Zio AT ECG Monitoring System, ZEUS System

The Zio AT ECG Monitoring System provides long-term, continuous ECG monitoring for adult patients to detect and report cardiac events, with its ZEUS System component utilizing an updated deep-learning algorithm for enhanced rhythm classification and analysis of single-lead ECG data. This modification aims to improve the accuracy and scope of arrhythmia detection for symptomatic and asymptomatic individuals in an ambulatory setting, facilitating clinician diagnosis.

The Zio AT ECG Monitoring System is designed for long-term cardiac monitoring in adult patients (18 years or older) who may be asymptomatic or experience transient symptoms like palpitations, dizziness, or syncope. It continuously captures, analyzes, and reports symptomatic and asymptomatic cardiac events using single-lead electrocardiogram (ECG) information. Patient-triggered and automatically-detected arrhythmia events are transmitted to a monitoring center, and a final comprehensive report, based on beat-to-beat analysis of the entire recording period, is generated for clinician review to aid in diagnosis. The system is intended for ambulatory, non-critical care patients. The key modification discussed pertains to the ZEUS System, the software component responsible for ECG analysis and reporting. This system, used by iRhythm’s Certified Cardiographic Technicians (CCTs) to generate reports, has updated its rhythm classification algorithm from a rule and machine-learning (ECGML) basis to a deep-learning (ECGDL) foundation. While the Zio AT Patch Recorder and Wireless Gateway Device components remain unchanged, the ZEUS System now integrates both ECGML and ECGDL labels. This update aims to enhance the processing and sorting of ECG data for improved rhythm detection, including an expanded list of rhythm types such as second-degree AV block type I and ectopic atrial rhythm, while maintaining its core function of enabling a complete ECG processing and analysis service.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the performance of the new deep-learning based rhythm classification algorithm in the ZEUS System compare to the previous rule and machine-learning implementation in terms of sensitivity and specificity for various arrhythmia types?; What specific architectural changes were made to the ZEUS System to accommodate the deep-learning algorithm, particularly concerning data processing and computational requirements?; Can the updated ZEUS System now identify or provide more nuanced classifications for the newly listed rhythm types (e.g., second degree AV block - type I, ectopic atrial rhythm) beyond what the original system could detect?; What were the key findings from the nonclinical verification and performance testing, specifically relating to the AAMI ANSI EC57:2012 and IEC 60601-2-47:2012 standards, that demonstrate the efficacy of the modified algorithm?; How does the integration of ECGML and ECGDL labels in the updated Result Integrator improve the accuracy or efficiency of the final report generation by Certified Cardiographic Technicians?